Skip to main content

Table 1 Clinicopathological characteristics in two cohors

From: ESR1 as a recurrence-related gene in intrahepatic cholangiocarcinoma: a weighted gene coexpression network analysis

Characteristics TCGA cohort (n = 29) Validation cohort (n = 30) P value
Age (years)
 ≤ 50 5 (17.2) 7 (23.3) 0.561
 > 50 24 (82.8) 23 (76.7)
Gender
 Female 16 (55.2) 10 (33.3) 0.091
 Male 13 (44.8) 20 (66.7)
Family history
 Yes 17 (58.6)
 No 11 (37.9)
Hepatitis virus
 Yes 1 (3.4) 15 (50.0)  < 0.001
 No 28 (96.6) 15 (50.0)
CA19-9
 IU/mL 39.2 (21.5, 223.0) 16.9 (12.3, 36.5) 0.008
Pathologic T
 T 1 18 (62.1) 11 (36.7) 0.089
 T 2 9 (31.0) 13 (43.4)
 T 3 2 (6.9) 2 (6.7)
 T 4 0 4 (13.3)
Pathologic N
 N 0 22 (75.9) 15 (50.0) 0.001
 N 1 3 (10.3) 15 (50.0)
 N X 4 (13.8) 0
Pathologic M
 M 0 25 (86.2) 30 (100.0) 0.052
 M 1/ M X 4 (13.8) 0
Tumor TNM stage
 Stage I 18 (62.1) 2 (6.7)  < 0.001
 Stage II 8 (27.6) 9 (30.0)
 Stage III 3 (10.3) 19 (63.3)
 Stage IV 0 0
MVI
 Yes 4 (13.8) 5 (16.7) 1.000
 No 25 (86.2) 25 (83.3)
ESR1 expression
 Copies 5.9 (4.8, 7.0) 3.4 (2.3, 8.0) 0.074
Recurrent status
 Yes 17 (58.6) 17 (56.7) 1.000
 No 12 (41.4) 13 (43.3)
Survival status
 Alive 15 (51.7) 16 (53.3) 1.000
 Dead 14 (48.3) 14 (46.7)
  1. TNM stage: ACJJ 6TH or 7TH TNM stage; Hepatitis virus: Hepatitis B and/or hepatitis C viruses; MVI: microvascular invasion